<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01486043</url>
  </required_header>
  <id_info>
    <org_study_id>CCI-11-00295</org_study_id>
    <nct_id>NCT01486043</nct_id>
  </id_info>
  <brief_title>Metformin and Transient Hyperglycemia</brief_title>
  <official_title>Metformin as an Adjunctive Therapy For Transient Hyperglycemia in Patients With Acute Lymphoblastic Leukemia During Induction Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether metformin is an effective adjunctive
      treatment for transient hyperglycemia in patients with acute lymphoblastic leukemia (ALL)
      undergoing induction chemotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ALL is the most common childhood cancer, representing one fourth of all cancers diagnosed
      under the age of 15 years. One of the most common side effects of ALL chemotherapy is
      transient hyperglycemia. Patients that develop this complication require treatment with
      insulin via injections to prevent severe medical complications such as dehydration, weight
      loss, ketoacidosis and life-threatening infections. Although insulin therapy is effective, it
      adds a lot of physical and psychological burden to patients because multiple daily insulin
      injections are required to achieve adequate blood glucose control.

      In this pilot study, investigators aim to examine the effectiveness of metformin as an
      adjunctive treatment for transient hyperglycemia. Investigators will be comparing two groups
      of subjects (up to 40 subjects per group). Patients in the treatment group will be
      prospectively recruited, and they will be treated with metformin in addition to insulin
      therapy. Investigators will compare the treatment group to a historical control group
      acquired via chart review. These patients will have been treated with insulin alone.

      Statistical comparison will be made between the two groups in terms of the length of insulin
      treatment, the total daily dose of insulin required, number of insulin injections, hemoglobin
      A1c level (measure of glycemic control over preceding 8- 12 weeks), and fructosamine level
      (measure of glycemic control over preceding 2-3 weeks).

      Investigators hypothesize that the use of metformin will result in fewer numbers of insulin
      injections and fewer days of insulin therapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The research project was terminated due to lower than projected patient recruitment within the
    period of time allowed for the study.
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of Insulin Therapy (Days)</measure>
    <time_frame>During the 30 days of induction chemotherapy (plus or minus 2 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Fructosamine Level</measure>
    <time_frame>At 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>At 1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Hyperglycemia</condition>
  <condition>Insulin Resistance</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Metformin and insulin therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 30-40 patients will be in the prospectively recruited treatment group, which will receive both metformin and insulin therapy for transient hyperglycemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>All subjects will be started on metformin 500 mg orally twice daily. The dose will be increased by 500 mg weekly as tolerated until subjects' blood glucoses are well controlled or until the patient reaches metformin 1000 mg PO BID.</description>
    <arm_group_label>Metformin and insulin therapy</arm_group_label>
    <other_name>Glucophage, Metformin HCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ALL patients on induction chemotherapy who develop transient hyperglycemia(definition
             of transient hyperglycemia: random blood glucose &gt; 200 mg/dL x 2)

          -  Adequate renal function (serum Cr &lt; 1.5 mg/dL in males, &lt; 1.2 mg/dL in females)

          -  Adequate hepatic function (AST &lt; 5x upper limit of normal)

        Exclusion Criteria:

          -  Patients with known diagnosis of diabetes or those that are already on oral
             hypoglycemic agents or insulin

          -  Allergy to metformin or any component of the formulation

          -  Patients with pancreatitis (lipase level &gt; 300 Units/L)

          -  Patients with active infection (positive blood culture within 48 hours of study
             registration)

          -  Patients with hemodynamic instability (PICU status, need for vasopressors within 48
             hours of study entry)

          -  Elevated hemoglobin A1c (greater than 6.0%)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamie R Wood, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pui CH, Burghen GA, Bowman WP, Aur RJ. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. J Pediatr. 1981 Jul;99(1):46-50.</citation>
    <PMID>6454771</PMID>
  </reference>
  <reference>
    <citation>Baillargeon J, Langevin AM, Mullins J, Ferry RJ Jr, DeAngulo G, Thomas PJ, Estrada J, Pitney A, Pollock BH. Transient hyperglycemia in Hispanic children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2005 Dec;45(7):960-3.</citation>
    <PMID>15700246</PMID>
  </reference>
  <reference>
    <citation>Lowas SR, Marks D, Malempati S. Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009 Jul;52(7):814-8. doi: 10.1002/pbc.21980.</citation>
    <PMID>19260096</PMID>
  </reference>
  <reference>
    <citation>Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev. 2002 Dec;16(4):225-43. Review.</citation>
    <PMID>12350366</PMID>
  </reference>
  <reference>
    <citation>Sonabend RY, McKay SV, Okcu MF, Yan J, Haymond MW, Margolin JF. Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. J Pediatr. 2009 Jul;155(1):73-8. doi: 10.1016/j.jpeds.2009.01.072. Epub 2009 Apr 25.</citation>
    <PMID>19394046</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2011</study_first_submitted>
  <study_first_submitted_qc>December 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2011</study_first_posted>
  <results_first_submitted>January 13, 2015</results_first_submitted>
  <results_first_submitted_qc>January 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2015</results_first_posted>
  <last_update_submitted>January 20, 2015</last_update_submitted>
  <last_update_submitted_qc>January 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Los Angeles</investigator_affiliation>
    <investigator_full_name>Dr. Jamie R. Wood</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Pediatrics; Director of Clinical Diabetes Programs at Children's Hospital Los Angeles, University of Southern California, Keck School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Induction chemotherapy</keyword>
  <keyword>Transient hyperglycemia</keyword>
  <keyword>Metformin</keyword>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Hyperglycemia</keyword>
  <keyword>Insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metformin and Insulin Therapy</title>
          <description>For the prospectively recruited arm (metformin plus insulin therapy), a total of 4 subjects were recruited. Two subjects were withdrawn from the study after laboratory studies revealed liver enzymes (AST) levels that were above that allowed for the study at the time. An additional 2 subjects were recruited in the study.
For the retrospective chart review portion of our study, 12 patients were included after conducting chart review of cases from January 2007 to August 2011.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2">Study terminated due to insufficient recruitment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin and Insulin Therapy</title>
          <description>Patients receiving metformin and insulin therapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.5" lower_limit="12" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1C</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" lower_limit="5.5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fructosamine</title>
          <units>uM</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="193" lower_limit="178" upper_limit="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title># of Day of Induction at Onset of Hyperglycemia</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="2" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Length of Insulin Therapy (Days)</title>
        <time_frame>During the 30 days of induction chemotherapy (plus or minus 2 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin and Insulin Therapy</title>
            <description>Patients receiving metformin and insulin therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Insulin Therapy (Days)</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Fructosamine Level</title>
        <time_frame>At 1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin and Insulin Therapy</title>
            <description>Patients receiving metformin and insulin therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Fructosamine Level</title>
          <units>uM</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" lower_limit="182" upper_limit="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin A1c</title>
        <time_frame>At 1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin and Insulin Therapy</title>
            <description>Patients receiving metformin and insulin therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1c</title>
          <units>percent of hemoglobin</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="4.3" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metformin and Insulin Therapy</title>
          <description>Patients receiving metformin and insulin therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jamie Wood</name_or_title>
      <organization>Children's Hospital Los Angeles</organization>
      <phone>323-361-7388</phone>
      <email>jawood@chla.usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

